Cargando…

Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia

PURPOSE: To investigate the exposure-toxicity relationship of bosutinib and to identify the target trough plasma concentration (C(0)). METHODS: The toxicity and C(0) of bosutinib in Japanese chronic myeloid leukemia (CML) patients were monitored every 2 weeks for the first 3 months of treatment, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mita, Akiko, Abumiya, Maiko, Miura, Masatomo, Niioka, Takenori, Takahashi, Saori, Yoshioka, Tomoko, Kameoka, Yoshihiro, Takahashi, Naoto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5899348/ https://www.ncbi.nlm.nih.gov/pubmed/29682402 http://dx.doi.org/10.1186/s40164-018-0101-1

Ejemplares similares

Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy
por: Abumiya, Maiko, et al.
Publicado: (2021)

Bosutinib for Chronic Myeloid Leukemia
por: Breccia, Massimo, et al.
Publicado: (2015)

Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial
por: Imamura, Keiko, et al.
Publicado: (2022)

Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study
por: Isfort, Susanne, et al.
Publicado: (2023)

Bosutinib in chronic myeloid leukemia: patient selection and perspectives
por: Isfort, Susanne, et al.
Publicado: (2018)

Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study
por: Isakoff, S J, et al.
Publicado: (2014)

Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase Domain
por: Levinson, Nicholas M., et al.
Publicado: (2012)

Bosutinib in the management of chronic myelogenous leukemia
por: Amsberg, Gunhild Keller-von, et al.
Publicado: (2013)

Pregnancy outcomes in patients treated with bosutinib
por: Cortes, Jorge E, et al.
Publicado: (2020)

Effects of CYP3A5 polymorphism on the pharmacokinetics of a once-daily modified-release tacrolimus formulation and acute kidney injury in hematopoietic stem cell transplantation
por: Yamashita, Takaya, et al.
Publicado: (2016)

Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia
por: Amsberg, Gunhild Keller-von, et al.
Publicado: (2013)

Induced pluripotent stem cell–based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients
por: Imamura, Keiko, et al.
Publicado: (2019)

Bosutinib-induced lung injury: a report of two cases and literature review
por: Watanabe, Naoki, et al.
Publicado: (2022)

Incident pulmonary arterial hypertension associated with Bosutinib
por: Yo, Shaun, et al.
Publicado: (2020)

Control of mammary tumor differentiation by SKI-606 (bosutinib)
por: Hebbard, Lionel, et al.
Publicado: (2010)

Bosutinib Inhibits EGFR Activation in Head and Neck Cancer
por: Segrelles, Carmen, et al.
Publicado: (2018)

Bosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia
por: Rassi, Fuad El, et al.
Publicado: (2013)

Bosutinib Therapy in Patients With Chronic Myeloid Leukemia: Practical Considerations for Management of Side Effects
por: Ault, Patricia S., et al.
Publicado: (2016)

Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia
por: Brümmendorf, Tim H., et al.
Publicado: (2020)

In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib
por: Redaelli, Sara, et al.
Publicado: (2015)

Synthesis of Bosutinib from 3-Methoxy-4-hydroxybenzoic Acid
por: Yin, Xiao Jia, et al.
Publicado: (2010)

Bosutinib Therapy Ameliorates Lung Inflammation and Fibrosis in Experimental Silicosis
por: Carneiro, Priscila J., et al.
Publicado: (2017)

Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia
por: Khoury, H J, et al.
Publicado: (2018)

High‐grade B‐cell lymphoma developed during the treatment of chronic myeloid leukemia with bosutinib
por: Takakuwa, Teruhito, et al.
Publicado: (2021)

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
por: Cortes, Jorge E., et al.
Publicado: (2018)

Population modeling of bosutinib exposure‐response in patients with newly diagnosed chronic phase chronic myeloid leukemia
por: Garrett, May, et al.
Publicado: (2023)

Protective effect of Bosutinib with caspase inhibitors on human K562 cells
por: Baty, Roua S.
Publicado: (2022)

Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies
por: Pagan, Fernando L., et al.
Publicado: (2022)

Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study
por: Ono, Takaaki, et al.
Publicado: (2022)

Successful treatment with nilotinib after bosutinib-induced pulmonary arterial hypertension recurrence following dasatinib in chronic myeloid leukemia in chronic phase
por: Takatsuka, Ibuki, et al.
Publicado: (2022)

Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation
por: Uz, B., et al.
Publicado: (2011)

Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review
por: Cortes, Jorge E., et al.
Publicado: (2018)

Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
por: Cortes, Jorge E., et al.
Publicado: (2016)

Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study
por: Hochhaus, Andreas, et al.
Publicado: (2020)

Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting
por: Muresan, B., et al.
Publicado: (2021)

Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations
por: Sweet, Kendra, et al.
Publicado: (2014)

Bosutinib: A Novel Src/Abl Kinase Inhibitor for Chronic Myelogenous Leukemia
por: Steinbach, Alison, et al.
Publicado: (2013)

Inhibition of Soluble Epoxide Hydrolase Attenuates Bosutinib-Induced Blood Pressure Elevation
por: Cui, Zhen, et al.
Publicado: (2021)

Rapid LC-MS/MS Bosutinib Quantification with Applications in Metabolic Stability Estimation
por: Attwa, Mohamed W., et al.
Publicado: (2023)

Bosutinib high density lipoprotein nanoformulation has potent tumour radiosensitisation effects
por: Dehghankelishadi, Pouya, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7ntr7k4ab8i9kep7lftrkjrnj7